NCT05612607View on ClinicalTrials.gov

Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

October 10, 2023

Study Completion Date

December 31, 2025

Conditions
Secondary Antibody Deficiency
Interventions
DRUG

Immunoglobulin replacement therapy (IGRT)

IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER